About: Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system
Creator	Murphy, Sean Friedman, Lawrence Massaro, Anthony Woolley, Ann Bohula, Erin Cadigan, John Cui, Jinghan Hibbert, Kathryn Januzzi, James Jones-O'connor, Maeve Kadar, Aran Khambhati, Jay Mccarthy, Cian Meyerowitz, Eric Morrow, David Natarajan, Pradeep Olshan, David Philippides, George Rehman, Saad Wasfy, Jason
source	Elsevier; Medline; PMC
abstract	BACKGROUND: Despite over 4 million cases of novel coronavirus disease 2019 (COVID-19) in the United States, limited data exist including socioeconomic background and post-discharge outcomes for patients hospitalized with this disease. METHODS: In this case series, we identified patients with COVID-19 admitted to 3 Partners Healthcare hospitals in Boston, Massachusetts between March 7th, 2020, and March 30th, 2020. Patient characteristics, treatment strategies, and outcomes were determined. FINDINGS: A total of 247 patients hospitalized with COVID-19 were identified; the median age was 61 (interquartile range [IQR]: 50–76 years), 58% were men, 30% of Hispanic ethnicity, 21% enrolled in Medicaid, and 12% dual-enrolled Medicare/Medicaid. The median estimated household income was $66,701 [IQR: $50,336-$86,601]. Most patients were treated with hydroxychloroquine (72%), and statins (76%; newly initiated in 34%). During their admission, 103 patients (42%) required intensive care. At the end of the data collection period (June 24, 2020), 213 patients (86.2%) were discharged alive, 2 patients (0.8%) remain admitted, and 32 patients (13%) have died. Among those discharged alive (n = 213), 70 (32.9%) were discharged to a post-acute facility, 31 (14.6%) newly required supplemental oxygen, 19 (8.9%) newly required tube feeding, and 34 (16%) required new prescriptions for antipsychotics, benzodiazepines, methadone, or opioids. Over a median post-discharge follow-up of 80 days (IQR, 68–84), 22 patients (10.3%) were readmitted. INTERPRETATION: Patients hospitalized with COVID-19 are frequently of vulnerable socioeconomic status and often require intensive care. Patients who survive COVID-19 hospitalization have substantial need for post-acute services.
has issue date	2020-08-19(xsd:dateTime)
bibo:doi	10.1016/j.eclinm.2020.100504
bibo:pmid	32838244
has license	no-cc
sha1sum (hex)	d7c8e74a8cb24d8c0e70342a94d002ef09db2dac
schema:url	https://doi.org/10.1016/j.eclinm.2020.100504
resource representing a document's title	Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system
has PubMed Central identifier	PMC7434634
has PubMed identifier	32838244
schema:publication	EClinicalMedicine
resource representing a document's body	covid:d7c8e74a8cb24d8c0e70342a94d002ef09db2dac#body_text
is schema:about of	named entity 'patients' named entity 'statins' named entity 'Emergency Department' named entity 'Hydroxychloroquine' named entity 'clinical trial' named entity 'Hypercoagulability' named entity 'nitric oxide' named entity 'post-acute' named entity 'Hispanic' named entity 'follow-up' named entity 'ICU' named entity 'statin' named entity 'Daiichi-Sankyo' named entity 'prophylaxis' named entity 'QTc interval' named entity 'morbidity' named entity 'follow-up' named entity 'risk of death' named entity 'all-cause mortality' named entity 'hydroxychloroquine' named entity 'QTc interval' named entity 'VTE' named entity 'pulmonary angiogram' named entity 'Amgen' named entity 'Thrombolysis' named entity 'Medicare and Medicaid' named entity 'ICU' named entity 'Merck' named entity 'malignancy' named entity 'Bayer HealthCare Pharmaceuticals' named entity 'VTE' named entity 'delirium' named entity 'SARS-CoV-2' named entity 'acute kidney injury' named entity 'Asian' named entity 'EKG' named entity 'Emergency Department' named entity 'vasopressors' named entity 'Pfizer' named entity 'azithromycin' named entity 'laboratory tests' named entity 'coronary vasospasm' named entity 'biomarker' named entity 'COVID' named entity 'Novartis' named entity 'Boston Scientific' named entity 'New York City' named entity 'VTE' named entity 'VTE' named entity 'stress cardiomyopathy' named entity 'anticoagulation' named entity 'azithromycin' named entity 'COVID' named entity 'sarilumab' named entity 'tracheostomy' named entity 'acute heart failure' named entity 'ICU' named entity 'research grant' named entity 'Hispanic' named entity 'antipsychotics' named entity 'interquartile range' named entity 'benzodiazepines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software